Signpath Pharma Inc

Signpath Pharma Inc is a clinical stage company based in Sandy, Utah, specializing in the development of heart-safe drugs. Their unique drug development platform, the CorreQT platform, effectively mitigates cardiac side effects associated with other medications, including cardiac arrhythmia and cardiac damage caused by chemotherapy.

One of their lead products, LipoCurc, is a proprietary liposomal formulation of curcumin that is administered intravenously. This innovative technology allows for active and sustained levels of curcumin that are over 1000 times greater than traditional oral dosing, without the usual cardiotoxicity associated with intravenous administration. LipoCurc has shown promising results in Phase 1a and 1b clinical trials, demonstrating no cardiac toxicity and signs of efficacy in end-stage cancer patients. Signpath Pharma is dedicated to addressing significant unmet medical needs and bringing innovative treatments through the clinic and into the marketplace.

Generated from the website